CCL4 and osteosarcoma: According to the evidence, CCL4 promotes integrin αvβ3 expression through the CCR5 receptor and then activates the FAK/AKT/HIF-1α signaling pathway, which subsequently inhibits miR-3927-3p expression and promotes integrin αvβ3 expression, as well as osteosarcoma cell migration (Figure 8).